Use of glycogen phosphorylase BB measurement with POCT in the diagnosis of acute coronary syndromes. A comparison with the ELISA method

Abstract

Key words: Acute coronary syndrome/Myocardial ischemia/Non-STEMI/Coronary by-pass/Laboratory markers of myocardial ischemia/CAD/GPBB/POCT/ELISABackground: Glycogen Phosphorylase BB (GPBB) is considered an early and specifi c marker of myocardial necrosis and ischemia. A POCT kit GPBB for diagnostic use has recently been approved.Aim: an evaluation of the correspondence of qualitative POCT GBPP measurements with ELISA test results. Material and methodology: 20 individuals with non-ST elevation myocardial infarction (non-STEMI) and 20 probands without acute coronary syndrome (ACS) were tested. GPBB (POCT, ELISA) in venous plasma (lithium-heparin) was assayed in all probands.Results: individuals with non-STEMI had signifi cantly higher GPBB ELISA values (32.3 vs. 6.1 μg/l; p < 0.01). GPBB sensitivity and specifi city for non-STEMI presence 6 hours after chest pain generation were 100 %. No proband was classifi ed in a diff erent subgroup with POCT of GPBB (positive/negative). GPBB POCT correlate with a non-STEMI diagnosis (χ 2 36.1; p < 0.01). Conclusion: GPBB POCT measurement is comparable with ELISA test results. GPBB analysis could expand the diagnostic palette in the fi rst hours after the onset of acute coronary syndrome.

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

“…H-FABP and GPBB are newer perspective markers for the early detection of myocardial ischemia and necrosis, recently evaluated in the diagnostics and risk stratification of acute coronary syndromes [68][69][70][71] . H-FABP is a relatively small cytoplasmic protein for the oxidation of fatty acids that is quite specific for cardiac muscle.…”

Comparative status of glycogen phosphorylase BB, myoglobin, and CK-MB for early diagnosis of acute myocardial infarction

“…[11,18] The early release of GPBB into the blood is a common result of the combination with of escalated glycogenolysis and increased permeability of cell membranes which is typical for myocardial ischemia and necrosis. [12,13,19] In this study, we found that GPBB was the most sensitive and specific biomarker to detect myocardial infarction when compared to MB and CKMB at the first 4 h ( Table 2). This finding is in agreement with Rabitzsch et al [20] and Cubranic et al [21] who also reported the highest sensitivity of GPBB in the early hours of chest pain.…”

“…Thus, GPBB which is connected to glycogen in a macromolecular complex that is structurally bound to sarcoplasmic reticulum believes to release from glycogen and then enters the bloodstream via the T-tubulus system within 1-4 ho of onset of AMI. [11][12][13] Hence, this study has been aimed to compare the sensitivity and specificity of GPBB with those of MB and CKMB within 4 h after the onset of chest pain.…”

New biomarker for acute ischaemic stroke: plasma glycogen phosphorylase isoenzyme BB

“…The utility of a biomarker is determined by diagnostic accuracy and convenience. The availability of a point-of-care platform that allows for rapid and simultaneous measurement of GPBB and cardiac troponins facilitates the frontline clinician’s ability to make timely management decisions 29. Overall, if confirmed in more diverse populations, GPBB could find utility as a stand-alone marker for identification of patients who may benefit from expedited confirmatory diagnostic investigation, particularly in those with small infarcts that typically present with minor, transient or equivocal symptoms.…”